We are committed to building a future with a more sustainable healthcare system. All patients should have cost-effective access to the medicines they need.
Biosimilars are biological products that are proven to have no clinically meaningful differences to their reference products.1 At a time when healthcare costs are rising, biosimilars offer a more affordable treatment option for patients compared with the reference biologics.2 And with increased availability of lower-cost biosimilars, patients will have improved access to the right medicine at the right time.
References: 1. US Food and Drug Administration. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. www.fda.gov/downloads/drugs/guidances/ucm291128.pdf. Accessed May 26, 2020. 2. The Biosimilars Council. Biosimilars in the United States. http://biosimilarscouncil.org/wp-content/uploads/2019/03/Biosimilars-Council-Patient-Access-Study.pdf. Accessed May 25, 2020. 3. Lee VWY, Cheng FWT. J Med Econ 2019. A review of biosimilar regulations and potential impact: Hong Kong perspectives. https://www.tandfonline.com/doi/full/10.1080/13696998.2019.1614008. Accessed May 18, 2020.